ヒト膵癌培養細胞株に対する制癌剤の増殖抑制効果に関する研究

概要

論文の詳細を見る
Sensitivities to anti-tumor drugs, Mytomycin C (MMC), Aclarubicin hydrochloride (ACR), Doxorubicin hydrochloride (ADR), Cisplatin and 5-fluorouracil (5FU), were examined using PK-1, PK-8, PK-9, PK-12, PK-14 and PK-16 cell lines derived from human pancreatic cancer. These cell lines showed different sensitivities to each of these anti-tumor drugs. The concentrations required for 50% growth-inhibition (IC50) after 2 hours of exposure were 0.096-0.35μg/ml for MMC, 0.0074-0.0076μg/ml for ACR, 0.033-0.23μg/ml for ADR, 0.35-1.9μg/ml for Cisplatin and 21-42μg/ml for 5FU. The IC50 of each anti-tumor drug decreased significantly after 48 hours of exposure. The combination of two out of three drugs, MMC, ACR and 5FU, resulted in a synergistic effect to inhibit the proliferation of pancreatic cancer cells.